Cited by 1,443Liver physiology and pathologyLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology

Open access
Mederacke, Ingmar, Hsu, Christine C., Troeger, Juliane S., Huebener, Peter, Mu, Xueru, Dapito, Dianne H., Pradere, Jean-Philippe, Schwabe, Robert F.·2013·Nature Communications

Abstract

Although organ fibrosis causes significant morbidity and mortality in chronic diseases, the lack of detailed knowledge about specific cellular contributors mediating fibrogenesis hampers the design of effective antifibrotic therapies. Different cellular sources, including tissue-resident and bone marrow-derived fibroblasts, pericytes and epithelial cells, have been suggested to give rise to myofibroblasts, but their relative contributions remain controversial, with profound differences between organs and different diseases. Here we employ a novel Cre-transgenic mouse that marks 99% of hepatic stellate cells (HSCs), a liver-specific pericyte population, to demonstrate that HSCs give rise to 82-96% of myofibroblasts in models of toxic, cholestatic and fatty liver disease. Moreover, we exclude that HSCs function as facultative epithelial progenitor cells in the injured liver. On the basis these findings, HSCs should be considered the primary cellular target for antifibrotic therapies across all types of liver disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms3823

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Besides hepatic stellate cells, portal fibroblasts, bone marrow-derived fibrocytes, and MSCs contribute to the pool of myofibroblasts to a minor extent.

    “Besides HSCs, other cells, including portal fibroblasts (particularly in cholestatic liver fibrosis), bone marrow-derived fibrocytes, and MSCs contribute to the pool of MFs as well, albeit to a minor extent [7, 13].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [13]

    The Introduction says bone marrow-derived fibrocytes may contribute to the myofibroblast pool to a lesser degree. The Results identify a small population of portal fibroblast-like myofibroblasts in cholestatic fibrosis, and the Discussion says they are less abundant than HSCs. Our copy does not identify MSCs as contributors, so that part of the claim is unsupported (searched: MSC, mesenchymal stem cells). (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Hepatic stellate cells are the predominant (>95%) source of collagen-producing cells and myofibroblasts in liver fibrosis.

    “hepatic stellate cells, the predominant (>95%) source of collagen-producing cells and myofibroblasts in liver fibrosis 15,43 .”

    From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [15]

    The Results (page unavailable in our copy) identify hepatic stellate cells as the dominant source of collagen-producing cells and myofibroblasts in the liver-fibrosis models studied. The >95% figure does not hold across those models: the paper reports 96.0% overlap with collagen-producing cells in one toxic-fibrosis model, but 82–85% of collagen-producing cells and 80–88% overlap with myofibroblast markers in biliary fibrosis. (LLM, conf=0.92)

    Experimental — accuracy not yet measured
  • In the fibrotic liver, activated hepatic stellate cells are the predominant source (>80%) of myofibroblasts.

    “In the fibrotic liver, activated HSCs (aHSCs) have been identified as the predominant source (> 80%) of MFs [7, 13].”
  • Hepatic stellate cells are central to liver fibrosis.

    “Hepatic stellate cells - liver-resident fibroblasts - are central to liver fibrosis 15 and interplay with hepatocytes via cell-cell contact and soluble mediators that support hepatocyte development and homeostasis 16,17 .”
  • Following injury, HSCs undergo a well-characterized activation process and become the primary fibrogenic cell type of the liver.

    “Following injury, HSCs undergo a well-characterized activation process and become the primary fibrogenic cell type of the liver [221, 227, 228].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F.
Affiliations
Columbia University (US)
Corresponding author
Schwabe, Robert F.
Venue
Nature Communications
Published
2013-11-22
Volume
4
Issue
1
Pages
2823-2823
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1965588383
Cited by
1,443
References
56
Citations by year
2026: 111 · 2025: 126 · 2024: 121 · 2023: 194 · 2022: 136 · 2021: 116 · 2020: 124 · 2019: 101 · 2018: 97 · 2017: 91 · 2016: 80 · 2015: 85 · 2014: 53 · 2013: 3 · 2012: 2
FWCI
45.87
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • American Liver Foundation (ME 3723/1-1, 1F31DK091980)
  • Case Western Reserve University
  • Deutsche Forschungsgemeinschaft (1F31DK091980, ME 3723/1-1)
  • National Institutes of Health
  • University of California, San Diego
  • National Cancer Institute (U54CA163111)
  • National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK76920, R01DK076920, F31DK091980, R01DK075830)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
hepatic stellate cells, liver fibrosis, myofibroblast origin, fibrogenesis, toxic liver injury, cholestatic liver disease, hepatic steatosis, antifibrotic therapy, bone marrow-derived fibroblasts, pericytes, epithelial progenitor cells
MeSH terms
Animals, Female, Liver Cirrhosis, Male, Mice, Inbred CBA, Mice, Inbred C57BL, Genes, Reporter, Integrases, Mice, Hepatic Stellate Cells, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review